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1. Introduction 
1.1. Neuropeptides 
Neuropeptides are intracellular peptides, composed of short chains of amino acids and found 
in brain tissue. They are often localized in axon terminals at synapses and are released as 
intercellular messengers that transmit information in the central nervous system, gastro-
intestinal tract etc. Many are also hormones released by nonneuronal cells. Neuropeptides 
can be divided and grouped according their site of synthesis and secretion or their structural 
or functional characteristics. Currently recognized neuropeptides include all hypothalamic 
releasing hormones, pituitary hormones, gastro-intestinal and brain peptides, some 
circulating hormones, opioide peptides, neurohypophyseal hormones etc (Siegel, 2006). Some 
neuropeptides are secreted by the nerve terminals with conventional neurotransmitters. But 
which are the differences between the classical neurotransmitters and the neuropeptides? The 
precursors of neuropeptides have at least 90 amino acids residues - larger than the precursors 
of the neurotransmitters. The synthesis of neuropeptides is carried in the neuronal soma and 
then is transported to the axonal ends. The secretion of neuropeptides requires lower 
concentration of intracellular Ca2+ in comparison to transmitters. After secretion the 
neuropeptides or their precursors are reused in the synapse. The concentration of the 
neuropeptides in the tissue is very low and they interact with the receptors at lower 
concentrations than neurotransmitters. Neuropeptides appearance and secretion are very 
plastic (Siegel, 2006). For example in pathological conditions, the number of endocrine cells 
that secrete neuropeptides can not only increase but also appear unusual locations as a result 
of additional stimulation (Gulubova et al., 2012).  
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1.2. Vasopressin 
Vasopressin (arginine vasopressin, AVP) is the first identified neuropeptide. AVP is a 
nonapeptide that is synthesized in magnocellular and parvocellular neurons, located in the 
paraventricular and supraoptic nuclei of the hypothalamus (Swaab et al., 1975). Most of 
vasopressin is released from the axonal terminals of magnocellular neurons directly iinto the 
bloodstream of the posterior pituitary. 
The effects of AVP are mediated mainly via V1and V2 receptors.  
V1 receptors are located on the vascular smooth muscle membranes. They are also found in 
myometrium and urinary bladder smooth muscle cell membranes. V1-receptor activation 
mediates vasoconstriction by receptor-coupled activation of phospholipase C and release of 
Ca2+ from intracellular stores via the phosphoinositide cascade (Thibonnier, 1992, Briley et 
al., 1994).  
V2 renal receptors are present in the renal collecting duct system and endothelial cells. 
Kidney V2 receptors interact (by the G protein complex) with adenylyl cyclase to increase 
intracellular cyclic adenosine monophosphate (cAMP) and cause retention of water (Orloff 
& Handler, 1967). 
V3 pituitary receptors (formerly known as V1b or AVPr1B), have central neural system 
effects, such as increasing adrenocorticotropic hormone production, activating different G 
proteins, and act via increasing intracellular cAMP (Thibonnier et al, 1997, Holmes et al, 
2001, Kam et al, 2007). 
The classical effects of vasopressin are mainly related to maintenance of water-electrolyte 
homeostasis and blood pressure. During the last years the data about the effects of this 
neuropeptide on brain function and behavioral reactions increase. The brain effects of 
vasopressin can be divided into two main types: those related to its peripheral effects such 
as hormone and focused on the maintenance of water balance. Others are associated with 
higher brain functions as learning, memory, emotion and they are independent of its 
hormonal effects (Frank & Landgraf, 2008). Vasopressinergic axons propelled from 
hypothalamus to many brain regions as hipocampus, septum, amygdala and brainstem, 
secrete AVP that acts as neurotransmitter. This extrahypothalamic vasopressin network is 
an anatomical basis of involvement of limbic-midbrain structure in processes of learning 
and memory. AVP facilitates consolidation and retrieval of memory (Kovacs et al., 1979)  
Vasopressin participates in formation of circadian rhythms and regulation of biological 
clock. The suprachiasmatic nucleus (SCN) is responsible for generation of circadian 
rhythmicity in mammalian brain and is an obvious source for a vasopressin innervation of 
GABAergic neurons located in this area (Hermes et al., 2000). A significant diurnal variation 
in vasopressin release in the SCN was detected, with the highest levels occurring during 
midday and a trough around midnight (Kalsbeek et al., 1995). It was demonstrated that 
melatonin synthesis was stimulated after local injection in pineal gland of vasopressin. Also 
the night melatonin plasma concentration was increased after prolonged period of water 
deprivation. These results show that vasopressin can modulate melatonin synthesis in the 
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rat pineal (Barassin et al., 2000). The suprachyasmatic nuclei, that are the main biological 
clock, contain vasopressinergic neurons. They demonstrate noticeable daily variation 
activity. In animals these vasopressin secreting neurons have very important role in the 
control of day/night rhythms. The reduced secretion of vasopressin in suprachyasmatic 
nuclei could contribute to the violation of sleep-wake rhythms during ageing and to 
development of depression (Kalsbeek et al., 2010).  
Vasopressin takes part in the regulation of maletypical social behaviors, vocal 
communication, aggression, and paternal care (Goodson & Bass, 2001). There are established 
projections of vasopressinergic neurons from the cells of the bed nucleus of the stria 
terminalis to the lateral septum with higher levels of density in nonaggressive animals. 
These lacalizations demonstrate the significance of vasopressinergic brain network in 
development of aggression (Compaan, 1993). 
AVP is a potent regulator of complex social maternal behaviors. The maternal cares that are 
vasopressin dependent were found to be independent of dam’s trait anxiety. The authors 
suggest that manipulation of AVP system could contribute to the treatment of mothers 
suffering from postpartum depression (Bosch & Neumann, 2008).  
Vasopressin, secreted in olfactory bulb is involved in the processing of stimuli that are 
important for social behaviors. In this anatomic region Tobin and coauthors (2010) have 
identified population of vasopressin neurons, most of which do not project outside the 
olfactory bulb. They discuss the importance of vasopressin secreting neurons in filtering out 
of the olfactory signals and in social recognition (Tobin et al., 2010). 
Vasopressin and corticoliberin, secreted from parvocellular portion of paraventricular nucleus 
in stress condition synergistically activate ACTH-adrenal axis. Aguilera supposed that in 
chronic stress there is preferential activation of vasopressin rather than corticoliberin and as a 
consequence a feedback mechanism is disintegrated (Aguilera, 1994). In contrast Zelena et al. 
(2006) demonstrate that AVP does not play critical role in stimulation of hypothalamic-
pituitary axis during chronic stress, but its role in acute stress is more important. 
1.3. Ghrelin 
Ghrelin is a multifunctional peptide hormone (28 amino acids) secreted from the cells of the 
diffuse neuro-endocrine system. Ghrelin-secreting cells are found from the stomach to the 
colon (in the oxyntic glands of the fundus and less in the small and large intestine) (Broglio 
et al., 2002; Lee et al., 2002; Inui et al., 2004). Ghrelin has been detected in the central nervous 
system, e.g. in arcuate nucleus and hypothalamus (Lu et al., 2002), in pancreas (Date et al. 
2002), in some cells of the immune system (lymphocytes and monocytes) (Mager et al., 2008) 
and also in human ovaries and testes (García et al., 2007). There is a hypothesis that ghrelin 
might have not only endocrine but also autocrine and paracrine mechanism of action. 
The presence of ghrelin receptor subtype GHS-R1a is detected in hypothalamus (n.arcuatus) 
and the pituitary gland, in multiple organs with nonendocrine and endocrine function 
(heart, lung, liver, kidney, pancreas, stomach, small and large intestines, adipose tissue, 
 
Neuroendocrinology and Behavior 114 
immune cells, gonads, thyroid gland, adrenal gland) (Broglio et al., 2003; Inui et al., 2004; 
Van Der Lely et al., 2004) and in gastrointestinal vasculature (Mladenov et al., 2006). They 
are also expressed by lumbosacral autonomic preganglionic neurons of the micturition 
reflex pathways (Ferens et al., 2010) 
The activation of the receptor causes the stimulation of the G-protein subunit Gα11. This 
leads to the activation of intracellular signaling cascades via the phospholipase C (PLC) 
(Vartiainen, 2009). 
The principal physiological action of ghrelin is the stimulation of secretion of growth 
hormone. Therefore ghrelin is a hormone with anabolic effect. It participates in the 
regulation of metabolism, energy homeostasis and feeding behaviors which are mediated 
via a complex neuroendocrine network (Van Der Lely et al., 2004). Ghrelin increases 
appetite and food intake and decreases fat utilisation as a metabolic fuel and increases fat 
storage in the adipose tissue. Ghrelin modulates gastic motility and emptying and gastric 
acid secretion and stimulates ileum peristalsis, most of these effects being vagally mediated 
(Ghigo et al., 2005). It induces fasted motor activity in the duodenum (Fujino et al., 2003). 
Ghrelin activity is mediated via enteric nervous system (Tack et al., 2006). 
Ghrelin and its receptors are present not only in the peripheral tissues but also in the central 
nervous system (Kang et al., 2011). Ghrelin functions as a peripheral hormone that is 
released mainly from the stomach and affects the hypothalamus, but also as a neuropeptide 
in hypothalamus (Kojima and Kangawa, 2005). Like other neuropeptides, Ghrelin is widely 
distributed in the brain in key areas of emotional regulation, and plays role as modulators of 
behavioural states (Kang et al., 2011). Ghrelin plays an important role in the regulation of 
energy balance by regulating food intake, body weight, glucose homeostasis and feeding 
behaviour which are mediated by a complex neuroendocrine network (Kalra et al., 1999; 
Van Der Lely et al., 2004). The regulation of energy balance is related to somatic growth and 
instinctive behaviour, including feeding, reproduction and emotion, and is a complex 
phenomenon involving interaction of the central and peripheral nervous systems, 
neuroendocrine system and gastrointestinal system (Matsuda et al., 2011). Ghrelin induces 
in the brain an orexigenic effect, modifies locomotor activity and also is involved in the 
control of psychophysiological functions and regulation of metabolism (Kang et al., 2011). 
The hypothalamic region of the brain plays very important role in the regulation of feeding 
and neuroendocrine functions (Kalra et al., 1999). Many types of neurons in the 
hypothalamus and related regions express ghrelin and some neuropeptides, such as, orexin, 
NPY, agouti-related peptide (AGRP), melanin-concentrating hormone (MCH) and other, 
which are implicated in the regulation of feeding behaviour and also in energy homeostasis 
in mammals (Eva et al., 2006; Kalra et al., 1999; Pickar et al., 1993). Ghrelin increases 
orexigenic effect and food intake but decreases energy expenditure thus inducing weight 
gain. (Kojima & Kangawa, 2005; Van Der Lely et al., 2004). Ghrelin exerts its central 
orexigenic effect through activation of hypothalamic neurons in the arcuate nucleus, 
important area involved in the regulation of energy balance and in addition it stimulates the 
neurons of other areas of the central nervous system, for example nucleus paraventricularis, 
dorsomedial parts of hypothalamus, and areas in the brain stem nucleus tractus solitarius 
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and the area postrema, which all take part in the modulation of appetite control (Lim et al., 
2010; Vartiainen, 2009). Ghrelin-secreting hypothalamic neurons send efferent fibers onto 
key circuits involved in the central regulation of energy homeostasis. They balance the 
activity of orexigenic neuropeptide Y/agouti-related peptide neurons in the arcuate nucleus 
and the activity of anorexigenic pro-opiomelanocortin (POMC) neurons that secrete alpha 
melanocyte stimulating hormone (α-MSH) and thus modulate the resultant effect (Van Der 
Lely et al., 2004).  
Several new intracellular targets/mediators of the appetite-inducing effect of ghrelin in the 
hypothalamus have recently been identified, including the AMP-activated protein kinase, its 
upstream kinase calmodulin kinase kinase 2, components of the fatty acid pathway and the 
uncoupling protein 2 (Lim et al., 2010). 
Recently, it has been demonstrated that ghrelin plays an important role in the regulation of 
central and peripheral lipid metabolism through specific control of hypothalamic AMP-
activated protein kinase (AMPK), a critical metabolic regulator of both cellular and whole-
body energy homeostasis (Kola et al., 2005).  
Centrally administered ghrelin has various effects such as arousal, increasing gastric acid 
secretion and gastrointestinal motility, inhibition of water intake and release of some 
hormones from the pituitary, mainly growth hormone (Hashimoto et al., 2011). 
Ghrelin may be synthesized in the hypothalamus. Ghrelin have hypothalamic actions on 
growth hormone-releasing hormone neurons (Sun et al., 2007). Ghrelin acts centrally to exert 
a global stimulatory effect on the hypothalamo-pituitary-adrenal axis. Ghrelin increases 
absolute whole adrenal gland weight and whole adrenal gland volume and elevates blood 
concentrations of ACTH, aldosterone and corticosterone (Milosević VLj et al., 2010). Ghrelin 
may function as a metabolic modulator of the gonadotropic axis, with inhibitory effects in 
line with its role as signal of energy deficit. These effects likely include inhibition of 
luteinizing hormone secretion, as well as partial suppression of normal puberty onset (Tena-
Sempere, 2008). 
Ghrelin-immunoreactive neurons are present in the paraventricular, dorsomedial, 
ventromedial and arcuate nuclei, areas important for circadian output. Contrary to the 
effects of ghrelin on appetite, growth hormone release and the sleep–wake cycle, little is 
known about the effects of ghrelin on circadian rhythms (Yannielli et al., 2007). 
Central ghrelin is also a gastroprotective factor in gastric mucosa. The gastric protection 
elicited by central ghrelin requires integrity of capsaicin-sensitive sensory neurons, which 
play an important role in gastric cytoprotection. Growing evidence indicates that the 
mechanisms triggered by peptides to increase resistance of the gastric mucosa involve 
changes in the release of gastric protective factors. Endogenous prostaglandins are involved 
in ghrelin gastroprotection (Sibilia et al., 2008). 
The short-term activation of AMPK in turn results in decreased hypothalamic levels of 
malonyl-CoA and increased carnitine palmitoyltransferase 1 (CPT1) activity. Ghrelin 
deficiency induces reductions in both de novo lipogenesis and beta-oxidation pathways in 
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the hypothalamus. There are reductions in fatty acid synthase (FAS) mRNA expression both 
in the ventromedial nucleus of the hypothalamus and whole hypothalamus, as well as in 
FAS protein and activity. CPT1 activity is also reduced. Chronic ghrelin treatment does not 
promote AMPK-induced changes in the overall fluxes of hypothalamic fatty acid 
metabolism in normal rats and this effect is independent of ghrelin status. In addition, 
ghrelin plays a dual time-dependent role in modulating hypothalamic lipid metabolism. 
(Diéguez C et al., 2010; Sangiao-Alvarellos et al., 2010)  
A reciprocal relationship exists between ghrelin and insulin, suggesting that ghrelin 
regulates glucose homeostasis (Sun et al., 2007). 
1.4. Angiotensin II 
The octapeptide Angiotensin II (Ang II) is the main effector of the renin-angiotensin system 
(RAS). Ang II is generated in circulation or locally in tissues in the kidney, blood vessels, 
heart, and brain and etc.  
The signal transduction mechanism for AT1 receptors is well known. AT1 receptors are 
distributed in adult tissues including blood vessel, heart, kidney, adrenal gland, liver, brain, 
and lung. These receptors activate phospholipase A2, phospholipase C, phospholipase D 
and L-type Ca2+ channels and inhibiting the adenylyl cyclase (Shokei & Hiroshi, 2011). 
AT2 receptors are ubiquitously expressed in developing fetal tissues, suggesting a possible 
role of these receptors in fetal development and organ morphogenesis. AT2 receptors 
expression rapidly decreases after birth, and in the adult. Expression of these receptors are 
limited mainly to the uterus, ovary, certain brain nuclei, heart, and adrenal medulla. In 
various cell lines, AT2 receptors activated protein tyrosine phosphatase was shown to 
inhibit cell growth or induce programmed cell death (apoptosis) (Kim and Awao, 2011). 
Ang II has a multifunctional role. It is general regulator of salt and water metabolism, thirst, 
sympathetic outflow and vascular smooth muscle cell tone. As a result Ang II acts as a 
principal controller of long term regulation of blood pressure (Robertson, 2005; Watanabe et 
al., 2005). Later, Ang II was found to exert long-term effects on tissue structure, including 
cardiac hypertrophy, vascular remodeling, and renal fibrosis (Watanabe et al., 2005). 
The key effector of peripheral renin-angiotensin system (RAS) - Ang II in circulation does 
not cross blood-brain barrier. Therefore it interacts on brain regions that lack the blood-brain 
barrier as circumventricular areas, organum vasculosum laminae terminalis, where Ang II 
stimulates salt appetite, thirst and vasopressin secretion (Fitts et al., 2000). Also, it influences 
neuronal activity in area postrema and takes part in central regulation of blood pressure 
(Otsuka et al., 1986). 
Many immunohistochemical studies demonstrate the distribution of all components of RAS 
- angiotensinogen, Ang I, Ang II and renin in several brain regions of rats. Immunoreactivity 
for Ang II was detected in neurons and vessels in the brainstem, cerebellum, hypothalamus, 
basal ganglia, thalamus and cortex while for angiotensinogen and Ang I were found in 
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neurons of the hypothalamic nuclei in rats (McKinley et al., 2003; Von Bohlen et al., 2006). 
AT1 receptor binding sites with higher density were localized in the lamina terminalis, 
hypothalamic paraventricular nucleus and the nucleus tractus solitaries, lamina terminalis 
and the subfornical organ. The median preoptic nucleus also contains membranes rich in 
AT1 receptors. All regions that are included in the regulation of cardiovascular functions as 
caudal ventrolateral medulla, and the midline raphe, also have AT1receptors (Allen et al., 
1999; Lenkei et al., 1997). In the midbrain -in the lateral parabrachial nucleus, substantia 
nigra and periaqueductal gray AT1 receptors are presented from moderate to high densities 
(Lenkei et al., 1997). These localizations of RAS brain components show that Ang II is 
involved in the regulations of thirst, drinking, facilitating vasopressor effects and secretion 
of vasopressin, adrenocorticotrophic and luteinizing hormones. Ang II also stimulates 
secretion of neurotransmitters such as noradrenaline and 5-hydroxytryptamine (5-HT) and 
inhibits acetylcholine release. The brain RAS appears to be also an important modulator of 
the blood pressure circadian rhythm and it influences renal renin release. 
Recent findings demonstrate that central effects of Ang II contribute to facilitated learning 
and enhance associative memory and learning possibly with differential effects on 
acquisition, storage and recall. Brain RAS is involved in the development of affective 
disorders and Ang II has a modulating effect of on anxiety (Georgiev & Yonkov, 1985). 
RAS receptors alterations have been found in some neurodegenerative disorders - 
Parkinson‘s and Huntington’s disease (Ge & Barnes, 1996). The number of AT1 receptors in 
caudate nucleus, putamen and substantia nigra was significantly decreased in Parkinson’s 
disease patients in comparison to controls. In Huntington’s disease patients, AT1receptors 
was found to be slightly decreased in putamen (Ge & Barnes, 1996). AT2 receptors that are 
localized in caudate nucleus was decreased in Parkinson’s and increased in Huntington’s 
disease patients. The receptor alterations were considerable; therefore the authors have 
concluded that brain RAS seems to decisively contribute to the pathology of the 
dopaminergic nigrostriatal pathway in these patients and may be a novel therapeutic target 
for neurodegenerative disorders (Savaskan, 2005). 
1.5. Cholecystokinin 
In 1928 Ivy and Oldberg extracted from dog duodenal mucosis a substance which injected 
intravenously contracted the gallbladder. The authors named this substance cholecystokinin 
(CCK). Later, Harper & Raper (1943) found a compound in this extract that stimulated the 
pancreatic secretion and called it pancreozymin. Purifying both hormones and determing 
their amino-acid sequention, Mutt (1980) proved them to be the same linear polypeptide, 
containing 33 amino-acid residues, and proposed the hybrid name “cholecystokinin-
pancreozymin”. Different CCK forms have been shown to exist: CCK-58, CCK-39, CCK-33, 
CCK-27, CCK-12, CCK-8, CCK-4, all of them containing a bioactive C-terminal. CCK-58 and 
CCK-39 are precursors of CCK-33 and by the degradation of the latter the shorter forms are 
obtained. Cholecystokinin octapeptide (CCK-8) is the most active one and is most widely 
spread in the gastro-intestinal tract and in the central nervous system. A cholecystokinin 
analogue, named caerulein, has been isolated from the skin of the frog Hyla caerulea. 
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CCK and gastrin possess identical 5 aminoacids at their C-terminals that are the biologically 
active part of both hormones. The dissimilarities in their potency and physiological activity 
are determined by the different positions of the Tyr-residue in the molecules of both 
peptides. When the Tyr-residue is in the 6th position, the peptide (gastrin) strongly 
potentiates the gastric secretion, its stimulating effect on the gallbladder contractions and 
pancreating secretion being much weaker. With the Tyr-residue in the 7th position, CCK 
markedly enhances the gallbladder motility and the pancreatic secretion. 
Immunohistochemical studies have shown that CCK is synthesized in the mucosal 
endocrine cells type I and type K of the small intestine, and in the endocrine cells type A of 
the pancreas. CCK-immunoreactivity has been also identified in the vagus nerve. 
Cholecystokinin is so called “brain-gut” neuropeptide – it is also produced by enteric 
neurons, and is widely and abundantly distributed in the brain. 
 The food intake in the small intestine is the main physiological stimulus for the CCK release 
– masts, proteins and aminoacids are the most powerful stimulants among the foods. The 
plasma CCK concentration increases from 1-2 pmol/l to 6-8 pmol/l after feeding (Cantor, 
1986). Cholecystokinin plays a key role in facilitating digestion within the small intestine – 
this peptide stimulates delivery into the small intestine of digestive enzymes from the 
pancreas and bile from the gallbladder. Recently it was shown that CCK-8 can reduce food 
intake by capsaicin-insensitive, nonvagal mechanisms (Zhang & Ritter, 2012). 
Mechanisms of secretion of cholecystokinin group peptides into the gastro-intestinal tract 
are as follows: a) Endocrine mechanism – the peptide is released by the endocrine cell in a 
blood vessel and is afterwards transported by the circulation to the effector cell; b) Paracrine 
mechanism – the peptide is released by the endocrine cell in the intracellular space, reaching 
afterwards the effector cell by diffusion; c) Neurotransmitter mechanism – the peptide is 
released by the nerve terminal in the synaptic cleft and affects afterwards the activity of the 
effector neuron; d) Neuroendocrine mechanism – the peptide is released by the neuron in a 
blood vessel. 
The peptide hormone CCK realizes its effects via binding to specific receptors localized on 
the cell membranes of the target organs. Two types of cholecystokinin receptors have been 
characterized so far: CCKA and CCKB which are approximately 50 % homologous (Dufresne 
et al., 2006). 
CCKA (gastro-intestinal) receptors. They prevail in the peripheral target organs (pancreas, 
gallbladder, small intestine), as well as in the vagus nerve afferent fibres, mediating the 
pancreatic enzyme secretion and the gallbladder and ileum motility (Crawley & Corwin, 
1994; Xu et al., 2008). CCKA-receptors have also been identified in some brain regions where 
they take part in the modulation of dopaminergic neurotransmission, and in the regulation 
of food behavior - satiety effect (Lieverse et al., 1995). 
CCKB (brain) receptors. They have been identified in various brain structures, as their 
number is largest in the cortex, hippocampus and limbic structures (Hokfelt et al., 1985). 
CCKB receptors, similar or identical to the peripheral gastrin receptors, have been 
demonstrated in peripheral organs, too. 
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Cholecystokinin is a major peptide hormone in the gut and a major peptide transmitter in 
the brain. Its synthesis requires endoproteolytic cleavage of proCCK at several mono- and 
dibasic sites by prohormone convertases. On one hand cholecystokinin is a classical gut 
hormone and a growth factor for the pancreas. On the other, the CCK gene is expressed also 
in large quantities in cerebral and peripheral neurons from where CCK peptides are 
released as potent neurotransmitters and modulators. Accordingly, cerebral CCK defects 
have been associated with major neuropsychiatric diseases such as anxiety, schizophrenia 
and satiety disorders (Crawley & Corwin, 1994; Liddle, 1997). 
CCK is also a key component of the aggression facilitating circuitry in the brain (Luo et al., 
1998), and it is released during inter-male fighting (Becker et al., 2001). In addition to its many 
aversive motivational/emotional effects, CCK also plays a role in more positively valenced 
motivational states, such as mating (Dornan & Malsbury, 1989; Markowski & Hull, 1995), drug 
addiction (Crespi, 2000) and brain reward processes (Degen et al., 2001, Josselyn, 1996). 
It was demonstrated that CCK is colocalized with dopamine in ventral striatal dopamine 
neurons (Hokfelt et al., 1980). Consistent with the neuronal colocalization and extensive 
overlap of expression between CCK and the dopaminergic system, CCK peptides have 
significant effects on dopamine mediated behaviors. Administration of CCK peptides 
exhibit many of the behavioral characteristics of antipsychotics including inhibition of 
conditioned avoidance responding (Cohen et al., 1982), inhibition of apomorphine-induced 
stereotypic behavior (Zetler, 1983), and inhibitionof amphetamine-induced hyperlocomotion 
(Schneider et al., 1983). Microinjection of CCK into the anterior nucleus accumbens inhibits 
dopamine release, inhibits dopamine-mediated behaviors and is blocked by a CCKA 
antagonist whereas injection into the posterior nucleus accumbens has the opposite effects 
and these effects are mediated by CCKB receptors (Vaccarino & Rankin, 1989, Crawley, 
1992). Thus, it appears that different CCK-based circuitries in the brain can facilitate both 
negative and positive emotional processes. It is also interesting to note that selective CCKB 
agonists that cross the blood brain barrier such as pentagastrin and CCK-4 are used to 
induce panic attacks in clinical studies. Consequently, a CCK agonist for schizophrenia 
would need to be either nonselective or CCKA selective. 
CCK was the first gut hormone discovered to have anoretic effects. Its actions include 
inhibition of food intake, delayed gastric emptying, stimulation of pancreatic enzyme 
secretion, and stimulation of gall bladder contraction. These effects are mediated via binding 
to CCK receptors on the vagus nerve. CCK administration to humans and animals inhibits 
food intake by reducing meal size and duration. However, at high dose nausea and taste 
aversion have been detected making CCK an unlikely candidate for an anti-obesity 
treatment. 
2. Materials and methods  
Wistar rats of both sexes weighting 200–250 g were used. The experiment was carried out in 
accordance with the national regulations and DIRECTIVE 2010/63/EU of the European 
Parliament and of the Council of 22 September 2010 concerning the protection of animals 
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used for scientific and experimental purposes. The animals were anesthetized with 
Nembutal 50 mg/kg intraperitoneally and exsanguinated. Abdominal cavity was opened 
and longitudinal strips from different parts of gastro-intestinal tract, urinary bladder and 
uterus horn were dissected out. The isolated organs were transferred immediately in cold 
Krebs solution 3 °C), containing following composition in mM): NaCl—118.0, KCl—4.74, 
NaHCO3—25.0, MgSO4—1.2, CaCl2—2.0, KH2PO4—1.2 and glucose 11.0.  
Longitudinal strips approximately 2 mm wide, 0.5 mm thick and 8 mm long) were dissected 
following the direction of the muscle bundles. The two ends of each strip were tied with silk 
ligatures. The distal end was connected to the organ holder; the proximal end was stretched 
and attached to a mechano-electrical transducer FSG-01 (Experimetria, Ltd., Hungary) via a 
hook. The preparations were mounted in organ baths TSZ-04/01, containing Krebs solution, 
pH 7.4, continuously bubbled with Carbogen (95% O2, 5% CO2). The organ baths were 
mounted in parallel above an enclosed water bath, maintaining the solution temperature at 
37 °C. Each smooth muscle strip was initially stretched to a tension of 1.0 g followed by 90 
minutes of equilibration. During this period, the smooth muscle strips were replenished 
with fresh Krebs solution at 15-th min, 60-th min and 75-th min.  
After initial period of adaptation, they were treated with the solution of different 
neuropeptides, and the obtained responses were registered.  
The phasic contractions of the smooth muscles before application of neuropeptide and the 
changes of motor activity, expressed as tonic contractions, relaxations or lack of reaction 
after treatment were recorded. The contractile activity signals were transduced by 
mechanical-force sensor, amplified, digitized and recorded using ISOSYS ADVANCED 
digital acquisition software, produced by Experimetria Ltd., Hungary.  
Chemicals and drugs 
Ang II (Sigma-Aldrich), vasopressin (Sigma-Aldrich), ghrelin (PolyPeptide Group) synthetic 
octapeptide of cholecystokinin (Squibb, USA), acetylcholine chloride (Sigma-Aldrich), 
hexamethonium chloride (Sigma-Aldrich) were solubilized in bidistillated water. All 
reagents for the preparation of Krebs solution were purchased from Sigma-Aldrich.  
Data analysis and statistic processing 
The recorded force-vs.-time curves permit determination of amplitudes and integrated force 
of contraction, the latter represented by the area under the curve (AUC), as well as defining 
of time parameters. Data acquisition and the initial conversion of the experimental data for 
the later analysis was performed with KORELIA – Processing software (Yankov, 2010). For 
later analysis, evaluation and identification was used KORELIA-Dynamics program. 
(Yankov, 2006; Yankov, 2011).  
Following time parameters were examined Figure 1:  
- Thc (s) – first half contraction time - time interval between the start of the smooth muscle 
contraction (SMC) and half-contraction moment (Thc = t hc - t 0);  
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- T(c-hc) (s) – second half contraction time - - time interval between the end of Thc and 
maximum peak of the SMC (T(c-hc) = tpeak-thc) 
- Tc (s) – contraction time - time interval between the start of the SMC and the moment of 
the maximum peak (Tc = t peak - t 0);  
- Thr (s) – half-relaxation time: time interval between the moment of the maximum peak 
tpeak and the moment when the curve decreases to Fmax/2 (Thr = thr - tpeak); 
-  Tchr (s) – contraction plus half-relaxation time: time between the start of the SMC and t hr 
(Tchr = thr – t0). 
 
Figure 1. Smooth muscle contraction (SMC) - graph and parameters. Fmax – maximal force of the SMC; 
Fmax/2 – half of maximal force of the SMC; t0 – start of SMC. t 0 = 0; thc – half-contraction moment; tpeak – 
the moment of the maximum peak Fmax; thr – the moment when the curve decreases to Fmax/2. 
The duration of the tonic contraction was defined from the beginning of the contraction, 
until the amplitude fell to 50%.  
For a more correct and acurate comparison between the parts of the gastrointestinal tract 
was performed normalization of the different intervals as a relative part of total length of the 
process Txn=Tx/chr). As a result the following normalized parameters were obtained: Thcn, 
Tcn, T(c-hc)n, Thrn.  
The gall bladder pressure in vivo was recorded in six conscious dogs weighing 18 to 20 kg. 
The animals were starved for 18 hours and were then anesthetized with chloralose (90 
mg/kg i.v.). Laparotomy was performed through upper midline abdominal incision. Gall 
bladder bile was aspirated with a syringe. The bile volume was between 30 and 40 ml. A 
small balloon mounted on the top of a polyethylene catheter was introduced into the gall 
bladder. Experiments were started four weeks after surgery and were carried out twice a 
week at of at least two-day intervals. The dogs were deprived of food, but were given water 
ad libitum for 18 hours before each trial. The balloon was filled with 1 ml distilled water and 
connected through a catheter to a pressure transducer. The changes in gall bladder pressure 
were measured in mmHg. The first 40-min records were used as controls. Cholecystokinin 
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octapeptide was then injected i.v. at increasing doses every 30 min. Atropine or 
hexamethonium was administered before cholecystokinin. 
Obtained data were processed by the statistical program Statistica 6.1, StaSoft, Inc. and 
presented as mean ± standard error. A P-value less than or equal to 0.05 was considered to 
be statistically significant.  
3. Results and discussions 
3.1. Urinary bladder 
The coordination of smooth muscle activity of the urinary tract in the process of the urine 
evacuation is regulated by complex, and not yet fully understood interactions between 
neural and hormonal control mechanisms (Dixon et al., 1997).  
The urinary bladder is innervated by three groups of peripheral nerves: sacral 
parasympathetic (Helm et al., 1982; Crowe & Burnstock, 1989; Gabella & Uvelius, 1990; 
Lasanen et al., 1992; Uvelius & Gabella, 1998), thoracolumbar sympathetic (Downie, 1981; 
Feher & Vajda, 1981) and sacral sensory (De Groat & Booth, 1993). According to the secreted 
mediator in the neural terminals innervation is classified as cholinergic, adrenergic, and 
non-adrenergic, non-cholinergic (NANC) (Callahan & Creed, 1986). In humans detrusor 
neurotransmission is exclusively cholinergic (Andersson et al., 1982; Sibley, 1984; Chen et 
al., 1994), while its adrenergic innervation is sparse, nonuniform, and it is considered non-
essential for micturition function (de Groat & Booth, 1984; Janig & McLachlan, 1987).  
A lot of different neuropeptides have been found to be synthesized, stored and released from 
organs in the lower urinary tract (LUT). Some of them are secreted from the peripheral neural 
terminals of the autonomic nervous system – vasoactive intestinal peptide (VIP), tachykinins 
(substance P), neuropeptide Y, calcitonin gene-related peptide, neurokinin A. Others which act 
by para- and autocrine mechanisms as angiotensin II are locally synthesized. The exact 
function of many of these peptides has not been fully established, however they may play role 
in a sensory and efferent innervation (de Groat & Kawatani, 1985; Burnstock, 1990; Maggi, 
1991) or serve as neuromodulators in the ganglia or at the neuromuscular junctions. Their 
actions have been thought to include mediation of the micturition reflex activation, smooth 
muscle contraction, potentiation of efferent neurotransmission and changes in vascular tone 
and permeability (Maggi, 1991, 1995; Hernandez et al., 2006). 
A few hormones with systemic circulation – vasopressin, oxytocin, are influencing bladder 
function (Uvelius B. et al., 1990; Romine & Anderson, 1985). These also include a newly 
discovered peptide ghrelin, which is secreted from the gastrointestinal tract, and stimulates 
contractions of smooth muscles of blood vessels and gastro-intestinal tract (Tack et al., 2006; 
Wiley & Davenport, 2002)  
Angiotensin II and urinary bladder 
There is insufficient information on the effect of Ang II on non-cardiovascular organ smooth 
muscles (Touyz & Berry, 2002). The interactions of the Ang II with the urinary bladder are of 
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particular interest regarding the genesis and treatment of the disorders of the micturition. 
The physiological effects of Ang II on the function of the urinary bladder and the 
transduction mechanisms which mediate it have not been fully elucidated. Ang II and its 
precursor Ang I cause dose-dependent contractions of muscle strips from rat urinary 
bladder (Andersson et al., 1992). According to experimental data of Anderson and co-
authors Ang II acts as a modulator in neurotransmission in the urinary bladder (Andersson 
& Arner, 2004). There are research data confirming that Ang II carries out its physiological 
effects by binding to membrane AT1 receptors (Tanabe et al.,1993), whose number on the 
surface of detrusor smooth muscle cells is regulated by the dietary content of sodium and 
potassium and the age of experimental animals (Weaver-Osterholtz et al., 1996; Szigeti et al., 
2005). AT1 receptors activate PLC, dihydropyridine-sensitive Ca2+-channels and inhibit 
adenylilcyclase, thus reducing intracellular cAMP concentration (Chiu et al., 1994). 
Our experiments show that the administration of Ang II solution to the smooth muscle stirps 
induce tonic contractions, in confirmation of the findings from other researchers concerning its 
effect on urinary bladder contractile activity. The increased amplitude of contraction following 
the administration of Ang II in the presence of increased extracellular Ca2+ provided evidence 
of additive synergism (Hadzhibozheva et al., 2009; Tolekova et al., 2010). The blockade of 
AngII-induced tonic contraction after the administration of blockers of T-type Ca2+ -channels 
unequivocally showed the role of transmembrane Ca2+ -influx in the initiation of smooth 
muscle contraction (Ilieva et al., 2008). The Ang II bindings to its membrane receptors, leads to 
activation of phospholipase C, which results in formation of inositol triphosphate, which 
triggers release of Ca2+ from sarcoplasmatic reticulum (SR). It's also well known that Ang II 
causes calcium-induced calcium release in smooth-muscle cells. Angiotensin II causes 
depolarization and opening of VDCC, providing additional Ca2+ influx from the extracellular 
fluid (Seki et al., 1999). When moving inside the cell, Ca2+ binds to ryanodine receptors and 
triggers supplementary Ca2+ release from SR stores (Berridge, 2008). In the experiment we 
applied specific inhibitor to this particular calcium-induced Ca2+ release mechanism. The 
resulting lack of tonic contraction suggested that this signaling pathway, leading to 
intracellular calcium increase is of greater importance for the development of detrusor muscle 
contraction than the inositol triphosphate pathway. Our experimental data also showed that 
the increase of calcium in extracellular fluid produced additive synergistic effect on Ang II-
mediated contraction of detrusor smooth muscle strips.  
The circulating AngII is formed in blood under influence of angiotensin–converting enzyme 
(ACE). During the last decade a lot of new facts that significantly broaden our knowledge of 
the RAS have been accumulated. Local tissue RAS was found in the blood vessels, heart, 
kidneys, small intestines, pancreatic tissue, liver, ovaries and brain (Paul at al., 2006). Other 
enzymes involved in RAS and physiologicaly active metabolites of Ang I and Ang II were 
also found (Waldeck et al., 1997; Miyazaki & Takai, 2006). 
A lot of recent studies have shown that Ang II acts as a cytokine and growth-like factor. 
(Kim & Iwao, 2000; Touyz & Berry, 2002). It regulates the smooth muscle mass in the 
bladder wall in normal and pathological conditions. Chronic bladder outlet obstruction 
causes changes in smooth muscle mass and connective tissue both in humans’ disease and 
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under experimental conditions in rats (Yamada et al., 2009). The application of ACE 
blocking substances significantly reduce the quantity of the newly synthesized collagen in 
the bladder, which is an indirect indicator of the effects of the local RAS on developing 
pathologic hypertrophic changes in the bladder. Phull and coauthors (2007) showed that 
applying angiotensin receptor anatagonists, reduced urethral resistance on rat models with 
stress urinary incontinence.  
The all main components of RAS – Ang I, Ang II and ACE are found inside bladder tissues 
(Weaver-Osterholtz et al., 1996). Tissue levels of Ang I and Ang II were higher than 
circulating levels, which confirms the existence of local synthesis in the urinary bladder, 
despite the lower measured activity of the angiotensin-converting enzyme, insitu is 
relatively This fact supports the hypothesis of auto- and paracrine actions of Ang II. It has 
been shown that Ang I also causes contraction of smooth muscle cells of the bladder, 
through the interaction with AT1 receptors. 
Ang II -mediated contraction is not completely blocked after administration of ACE 
inhibitor (Lindberg et al., 1994). These facts indicate the existence of alternative pathways for 
the synthesis of Ang II. Urata and co-authors show that in the heart of the main enzyme 
converting Ang I to Ang II is a serine protease human himase (Urata et al., 1990). Andersson 
and co-authors found that application of enalaprilat not fully block contraction of urinary 
bladder detrusor stripts induced by Ang I (Andersson et al., 1992). This means that the 
remaining contractile effect is due to separate mechanism of Ang II formation. 
Vasopressin 
Besides its vasoconstrictor activity, AVP is involved in the modulation of the intrinsic 
smooth muscle activity of the urinary system. Vargiu and coauthors demonstrate that AVP 
increases the contractile activity of upper urinary tract that is most pronounced in small 
calices, which are the main pacemaker of the urinary tract and is mediated by  
V1 receptors (Vargiu et al., 2004). It remains unaffected by the blockade of sodium channels 
with tetrodotoxin. However, the application of nifedipine and L-type calcium channels 
blockers reduced spontaneous and AVP-induced activity of smooth muscles of the upper 
urinary tract (Vargiu et al., 2004). This demonstrates the importance of transmembrane 
calcium influx for the contractile activity of smooth muscle of the lower urinary tract. 
There is a data that shows the presence of V1-receptors in smooth muscle of the urinary 
bladder, who’s binding to AVP leads to activation of the inositol-triphosphate (IP3) pathway, 
similarly to binding to Ang II (Crankshaw, 1989; Dehpour et al., 1997). It was found that the 
removal of extracellular calcium prevents the effects of AVP, suggesting it possible 
involvement in the activation process (Crankshaw, 1989). In our experiments AVP application 
to the bladder detrusor smooth muscle strips stimulates powerful tonic contractions. This 
result supports currently available information on this issue (Uvelius et al., 1990).  
Comparison of the effects of Ang II and AVP on contractile activity 
Ang II and AVP, accomplish their effects through the formation of the second messenger 
IP3. The comparison of the independent effects of Ang II and AVP on urinary bladder strips 
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shows contractions with approximately equal amplitude, but with integrated muscle force 
significantly increased after the application of AVP (Figure 2, Table 1) (Tolekova et al., 2010).  
 Fmax.g) AUCgs) Thc s) Tc-hc) Tc s) Thr s) Tchrs) 
AVP 1,55±0,16 761,29±113,3 28±4 99,6±15 127,4±18 255,3±35 382,7±43 
Ang II 1,73±0,26 115,13±20,7 12,6±1,6 19,7±5 32,3±3,3 61,5±13,6 93,7±13,3 
Table 1. Force and time-parametes means±SE) of Ang II- and AVP-induced contractions.  
 
Figure 2. Angiotensin II- and AVP – induced contractions after processing of signals with specialized 
software. 
For detailed study and comparison of the tonic contractions under the influence of the two 
peptides, we are using time parameters, described in Yankov (2011) (Figure 1, Table 1), 
generated after signal processing with specialized software (Yankov, 2010). The similar 
parameters were used for investigation of the contractions of the skeletal muscles (Raikova 
& Aladjov, 2004). Our research results show that Ang II causes contractions with a shorter 
duration (shorter time for reaching Fmax/2 and Fmax). The AVP-induced response reaches 
significant AUC value at the expense of the lower rate of increased and decreased contractile 
activity (longer duration of Thr and Tchr). The greater length of AVP contraction time is 
mainly due to longer T(c-hc) period. It is particularly interesting that despite acting through 
the same transduction pathways, Ang II and AVP cause tonic contractions with different 
measured force. We assume that this difference, especially the higher speed of relaxation, 
might be related to the specific Ang II metabolism in bladder cells. Production of Ang III 
and Ang 1-7 may be a cause of the faster rate of relaxation (Varagic et al., 2008). The 
interactions of the two peptides – Ang II and AVP with the ion channels of the smooth 
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muscle membrane may contribute additionally to the differences in the computed 
parameters and shape of the contraction graphic. There are existing data about the effect of 
AVP on the potassium channels of brain cells after fluid percussion brain injury indicating 
that AVP inhibited activity of the KATP and KCa channels (Armstead, 2001). It is known 
that the urinary bladder smooth muscle cells have a number of potassium channels, 
including ATP-dependent K channels and Ca2+-dependent K channels (Petkov et al., 2001). 
Interaction with those channels could be a possible explanation for the prolonged duration 
of AVP action on smooth muscle contractions.  
On the other hand, Ang II stimulates the activity of L/T-type voltage dependent calcium 
channels in vascular smooth muscle cells (Lu et al., 1996). We can suggest that in the smooth 
muscle cells of the rat bladder a similar effect takes place. 
Role of extracellular calcium for Ang II- and AVP-mediated contractions of smooth muscle cells 
The increase of concentration of the extracellular Ca2+ exerts a synergistic effect on Ang II- 
and AVP-mediated contractions. The raise of the amplitude of contraction is a consequence 
of increased transmembrane calcium influx due to the higher electrochemical gradient. As a 
result the intracellular calcium concentration is maintained at the higher level than the level 
of the resting state. There is evidence that this pattern of variations in calcium concentration 
contributes to the development of the mechanism of "locking" of the smooth muscle cells 
(Tanaka et al., 2008). We suppose that the above mentioned significant difference in AUC is 
due to the manifestation of this mechanism (Tolekova et al., 2010). 
Ghrelin 
The endocrine effects of the peptide ghrelin on various organs and systems are not well 
examined; however it is known that it stimulates the motility of digestive tract (Tack et al., 
2006). On the vascular smooth muscle it exercises a dilatatory influence which is comparable 
to that caused by adrenomeduline (Wiley & Davenport, 2002). Binding of ghrelin to the its 
membrane receptors in some tissues triggers signal transduction mechanism via Gq protein 
and results in activation of PLC and release of IP3 and Ca2+ (Davenport et al., 2005). There 
are no data in the literature regarding the effects of ghrelin on urinary bladder smooth 
muscle. The presence of ghrelin receptors on the membranes of detrusor smooth muscle 
cells is not proven yet. Therefore it is interesting to investigate whether and how ghrelin 
affects the bladder detrusor and if so by which signal transduction mechanism. Moreover, 
there is not existing published comparison between the effects of AVP and Ang II on 
detrusor contractile activity as well as effects of calcium and ghrelin on the smooth-muscle 
contractions mediated by these peptides.  
Does Ghrelin have an effect on a urinary bladder? 
The receptors for ghrelin described in the literature mediate their activity with activation of 
PLC and subsequent increase in concentration of intracellular calcium (Davenport et al., 
2005). Therefore, the application of ghrelin on muscle strips of urinary bladder would lead 
to the occurrence of tonic contractions. During the experiments we found no statistically 
significant changes in contractile activity after application of ghrelin as compared to the 
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spontaneous activity. The effects of ghrelin are displayed only when it is applied in 
combination with other peptides – Ang II or AVP. In combination with Ang II, ghrelin 
reduces its contractile effect on the bladder (Ilieva et al., 2008, a). The combination of ghrelin 
with AVP leads to similar yet significantly less manifested decrease, especially in the AUC. 
Based on these results we can assume that the urinary bladder possesses receptors for ghrelin, 
different from those in the digestive tract, with respect to the intracellular signaling 
mechanism to which they are coupled. The significant reduction in the amplitude of Ang II-
induced contraction as well as the partial reduction of AVP-provoked contraction after ghrelin 
application could be explained by the interaction between signal transduction pathways by 
which the both peptides act. To our knowledge, this is the first in vitro study demonstrated the 
inhibitory effect of ghrelin on bladder motor activity. Our results were confirmed by Matsuda 
et coauthors (2011). They showed in experiments in vivo that intracerebroventricular 
administration of Ghrelin increases bladder capacity dose dependently.  
It is likely that ghrelin acts through the second messenger cAMP. Activation of this signal 
pathway causes relaxation of smooth muscles by decreasing the activity of miosinkinase and 
stimulating Ca2+-efflux. This effect of ghrelin could be explained with interactions between 
the two types of transduction pathways, which have opposite effects (Rasmussen & 
Rasmussen, 1990; Churchill, 1985). 
3.2. Gastro-intestinal tract 
Angiotensin II 
Angiotensin II has potent contractile effect on smooth muscles in the gastro-intestinal tract 
(GIT). The question for the exact effects of Ang II on GIT remains still opened. Local RAS or 
parts of it had been found in rat rectum (De Godoy et al., 2006), rat small intestine, and in 
the guinea pig gall bladder (Leung et al., 1993). The role of Ang II had been confirmed in the 
development of diseases such as the gastro-esophageal reflux (Fändriks, 2010), incontinence 
of internal anal sphincter (De Godoy et al., 2006; Rattan et al., 2003), and Crohn's disease 
(Fändriks, 2010; Wang et al, 1993) as well as other inflammatory and motility disorders of 
the GIT (Fändriks, 2010). 
Most of the effects of Ang II concerning the smooth muscle contractile activity of GIT are 
associated with AT1 receptors (Fändriks, 2010; Fan et al., 2002; Hawcock & Barnes, 1993; 
Rattan et al., 2003). AT2 receptors are also described in GIT (Fändriks, 2010; Fan et al., 2002; 
De Godoy et al., 2006; Hawcock & Barnes, 1993; Ewert et al., 2003; Leung et al., 1993; De 
Godoy et al., 2002). Although different signaling pathways have been assumed, for example 
activation of various phosphatases, cGMP -NO system etc. (Ewert et al., 2003; Dinh et al., 
2001), their actual signal transduction is not quite elucidated. AT2 receptors are associated 
with the exchange of water and salts, sodium hydrogen carbonate secretion in the 
duodenum (Fändriks, 2010) and the secretion of nitric oxide in pig’s jejunum (Ewert et al., 
2003). The significance of AT2 receptors for GIT motility has not been established yet. It is 
supposed that they have the opposite effect of AT1 receptors (Gallinat et al., 2000), but as a 
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factor for the smooth muscle relaxation they had been proved only for the internal anal 
sphincter (De Godoy et al., 2006; De Godoy & Rattan, 2005).  
There is not enough information in the literature, regarding to the comparative 
characteristics of Ang II - induced responses from the various segments of GIT. Dose - 
dependent curves, which are commonly used as a method for studying the provoked 
smooth muscle contractions (Fändriks, 2010; Fan et al., 2002; Hawcock & Barnes, 1993; 
Leung et al., 1993; Park et al., 1973), could give information about the effective doses and 
maximal responses, but not a data for other important characteristics of the smooth muscle 
contractions. The different phases of the contraction in the various segments of the GIT, 
were not clarified and analyzed by application of a time-parameter analysis, as it was made 
in the study of the skeletal muscle contraction (Raikova & Aladjov, 2004). For comparison 
and detailed analysis of Ang II contractile effects of Ang II on the different segments of 
longitudinal strips from rat GIT we are using again time-parameters.  
The amplitudes and integral muscle force of different segments from GIT in our experimental 
study showed marked correlation (r=0.88, p<0.005). The duodenal muscle strip demonstrated 
the lowest amplitude and smallest integral force of contraction - 0.55±0.13 g, 41.43±15.52 gs. 
The amplitudes of the registered angiotensin II-induced contraction from stomach (1.14±0.13 
g), jejunum (1.11±0.14 g) and ileum (1.09±0.16 g) are similar and there are not statistically 
significant differences between them. But stomach integral force (178.09±19.63 gs) is 
significantly greater than that of duodenum and other intestines and is equally powerful as 
that of the colon. Under influence of Angiotensin II, rectum developed highest amplitude of 
contraction 4.74±0.65 g and most powerful integral force - 328.43±75.23 gs.  
The analysis of time parameters of Ang II-mediated contractions indicated that the gastric 
response to Ang II required more time to develop: the time to reach Thc and Tc parameters 
was 29.09± 2.53 s and 78.18 ± 5.87 s respectively. This tendency for a slower progress of the 
reaction was maintained during the whole contraction of the stomach and its Tchr was 224.90 
± 18.45s. All of the registered intestinal contractions showed similar values for Thc and Tc 
parameters. For the remaining two time - parameters - Thr and Tchr, the results from the 
intestinal contractions were analogous, with exception of the ileac contraction, which Thr 
(106.33±9.89 s) and Tchr (141.08±9.48 s) were significantly prolonged. After normalization of 
time-parameter, it was shown that jejunum and colon have similar pattern of contractions 
and relaxation (Figure 3). The relaxation takes one half of the process and the first and the 
second part of the contraction are with almost identical proportion, The other parts of GIT - 
stomach, duodenum and rectum have almost similar pattern of contractions and relaxations. 
Only ilium differs from these two groups. The relative part of its relaxation was 0.75 from 
whole duration of process. Application of the time parameters clearly shows the presence of 
bilateral symmetry in the responses of the gastrointestinal tract. 
The amplitude comparison of the Ang II-induced contractions divides the isolated smooth 
muscle preparations into two groups. The stomach and the small intestines form one group, 
and the large intestines form another. It is obvious that the large intestines are more 
sensitive to Ang II and react with more powerful contractions. There is a gradual increase in  
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Figure 3. Normalized time-parameters of contractile activity of different GIT segments, induced by 
Angiotensin II. 1-Thcn, 2-T(c-hc)n and Thrn. 
the muscle response to Ang II along the rat intestine, which confirms previous studies of 
Ang II - provoked intestinal contractions (Ewert et al., 2006). In the literature there are 
evidences about the uneven distribution of the Ang II receptors in most tissues of the adult 
organism (Steckelings et al., 2010). Regarding GIT there has been described an unequal 
density of AT1 receptors (Fändriks, 2010), which could explain the obtained results. From 
the other side, the duodenal contraction has the smallest amplitude, which strongly 
differentiates the reaction of the duodenum from the other GIT segments. This could be due 
to low density of duodenal Ang II receptors and with a local production of NO by the 
duodenal mucosa (Aihara et al., 2005). 
There had been established several transduction pathways of Ang II- induced SMC (Dinh et 
al., 2001; Romero et al., 1998). The modulating effect of Ang II on different ion currents also 
had been reported (Chorvatova et al., 1996; Romero et al., 1998). According to Thc and Tc 
parameters, there is a marked difference between the stomach from the one side, and the 
intestines from the other. All of the studied intestinal segments showed similar speed of 
contraction, while the duration of the stomach reaction was far longer. That data suggest a 
possible transduction pathway for SMC of the stomach, different than in the others GIT 
segments. 
Some authors consider possible competitive interactions between AT1 and AT2 receptors in 
smooth musculature of the intestine, which supports some previous statements that the 
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magnitude of the response to Ang II depends on the expression of both receptors (Ewert et 
al., 2006). It had been demonstrated that only AT1 receptors are relevant for the maximum 
response in ANG-induced contractions (Hawcock & Barnes, 1993; Fändriks, 2010; Fan et al., 
2002; Rattan et al., 2003; Ewert et al., 2006; Fändriks, 2010). Despite the existing assumptions 
that stimulation of AT2 receptors may have the opposite effect than that of AT1 (Gallinat et 
al., 2000), the role of AT2 receptors for the relaxation phase of the SMC in GIT is not 
examined. The importance of AT2 receptors for the relaxation of the rectum has been 
described only (De Godoy et al., 2006; De Godoy & Rattan, 2005). Regarding the time 
parameters for relaxation, the stomach again showed the slowest response. In this case the 
ileum indicated significantly prolonged reaction compared to the other intestinal segments. 
The reason for that difference may be the complete absence or the low density of AT 2 
receptors in the ileum (Fändriks, 2010).  
In conclusions the observed differences in the Ang II - induced gastro-intestinal contractions 
may be due to: 
 Variation in the Ang II receptor subtypes distribution. Regarding GIT there has been 
described an unequal density of Ang II receptors. This uneven distribution of the 
receptors could explain the differences in the amplitude and duration of Thc of SMC. 
 Counteraction between Ang II receptor subtypes. Competing actions between Ang II 
receptors have been discussed in the smooth musculature of rat small intestine. The 
relative receptor expression is a determinant of the magnitude of response to Ang II. 
This might be of importance for the duration of muscle contraction after reaching the 
maximal response - expressed by Thr. 
 Activation of various transduction pathways. There is data that Ang II can modulate 
ionic conductance in distinct tissues. The different duration of the interval between Thc 
and Tc, as well as Thr may be due to the involvement of some membrane ion channels. 
 Presence of local rennin - angiotensin system and formation of numerous of active 
angiotensin derivates. It is proven that most tissues are the source, target and 
degradation site of Ang II. Furthermore, local rennin - angiotensin system or parts of it 
had been found in rat rectum and rat small intestine. This is another possibility which 
could explain the obtained data about the phase of relaxation and force of SMC. 
 The use of time - parameters significantly contributes to the analysis of the contraction 
process and permits a good comparison of the Ang II – induced responses. Presentation 
of the time parameters as part of the total contraction normalization) gives an idea for 
the development of the process in the different time intervals. 
 The obtained results provide a direction for further research work on Ang II-mediated 
contractions of GIT and for clarifying the exact role of the AT1 and AT2 receptors in the 
different phases of SMC. 
Ang II – provoked rectal response. Comparison with the urinary bladder response 
The application of Ang II on the rectal preparation caused a development of expressed tonic 
contraction, which amplitude and integral muscle force were significantly greater than those 
of the bladder. The higher amplitude is achieved at the expense of the second half of the 
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contraction. The higher values of the absolute and normalized time – parameters for this 
interval are the evidence. The difference in the total muscle mass of the preparations 
significantly contributes for these distinctive force parameters. It is worth noted, that the 
time-parameters (absolute and normalized) of Ang II – mediated bladder and rectal SMC, 
with the exception of T(c-hc) parameter, do not indicate significant differences (Figure 4). This 
proves the suggestion that in the urinary bladder and rectum the Ang II - mediated 
contractions are developed by similar mechanisms. Moreover, this assumption is an indirect 
evidence for an approximately equal density of Ang II receptors in these two organs. The 
uniformity of response to Ang II is supported by the fact that it the rectum a local renin-
angiotensin system has also been established (De Godoy & Rattan, 2006). It could be 
considered again that the locally generated metabolites of Ang II contribute for this pattern 
of the contraction process. 
 
Figure 4. Normalized time-parameters of urinary bladder and rectum Ang II – induced contractions. 
All of the normalized time-intervals were calculated as a relative part from Tchr. 
Does AVP have an importance for the motility of the gastro-intestinal tract? 
Dose-dependent effects of AVP on gastro-intestinal tract from different species were 
observed, but regarding the rectal musculature the information is insufficient and 
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controversial (Ohlsson et al., 2006). AVP has been shown to increase the gastric and 
duodenal motility in humans and rabbits (Ohlsson et al., 2006; Li et al., 2007), as well as 
colonic peristalsis, but the expression of the AVP receptors in intestine has not been 
examined yet (Ohlsson et al., 2006). Some authors have demonstrated that AVP increase the 
gastro-intestinal motility via the oxytocin OT1 receptors, but the experiment is only for 
stomach and duodenum from rabbits (Li et al., 2007). 
In our study, the application of AVP does not significantly alter the characteristics of the 
spontaneous phasic contractile activity of gastro-intestinal segments except this of stomach. 
This could be explained with the absence of AVP receptors type V1, which are present in the 
urinary bladder. In rectal musculature V2 receptors could be presented – in such a case, the 
rectum as a terminal department of gastro-intestinal tract shows analogy with the distal and 
the collecting tubules of the kidneys. This is still an assumption that remains to be 
investigated. 
Gallbladder 
The mechanical activity of the gallbladder of conscious dogs consisted of spontaneous 
rhythmic contractions with a frequency of 2 to 5 cpm. Fluctuations of the tone were also 
observed. Bolus injection of cholecystokinin octapeptide i.v. produced a dose-dependent 
increase in gallbladder pressure (Figure 5A). Atropine decreased gallbladder pressure and 
reduced or even abolished the cholecystokinin action (Figure 5B). Hexamethonium led to 
gallbladder relaxation and also greatly reduced the gallbladder response to cholecystokinin 
octapeptide (Figure 5C). 
The mechanisms through which atropine or hexamethonium inhibit cholecystokinin-
produced gallbladder contractions under in vivo conditions are not understood. One 
possible explanation might be that the excitatory effect of cholecystokinin on the gallbladder 
is mediated by acetylcholine release from cholinergic neurons at pre- and post- ganglionic 
level. Another possibility is that atropine and/or hexamethonium are able to block the 
release of endogenous cholecystokinin from the endocrine cells or neurons. This suggestion 
is supported by the fact that vagotomy abolish gallbladder response to cholecystokinin after 
acidification (Fried et al., 1983), infusion of fat into the duodenum (Magee et al., 1984) or 
after drinking water (Sundler et al., 1977). The release of CCK in the circulation in response 
to fat or other meals is also reduced after vagotomy or atropine. It is also possible that 
atropine or hexamethonium blockade of cholinergic input to the gallbladder may unmask 
the release of neuronal inhibitory influence which could then compete with the release of 
CCK. Such inhibitory agents could be somatostatin and vasoactive intestinal peptide (Lenz 
et al., 1993; Milenov et al., 1995). 
Uterus 
It has been reported that in the uteri of a number of species, local production of Ang II and 
the enzymes for its synthesis are present. Besides the proven contractile effect of Ang II on 
the uterine arteries, research in this area showed that myometrium is also sensitive to the 
effect of this octapeptide (Keskil et al., 1999).  
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Figure 5. CCK-8 (2.5; 5 and 10 ng/kg i.v.)-induced gallbladder pressure before (A) and after atropine (B) 
(20 g/kg i.v.) or hexamethonium (C) (1 mg/kg i.v.). Means ± S.E.M. of 12 experiments in 6 conscious 
dogs are presented, P < 0.01. 
There is substantial evidence for the involvement of AVP in conditions of uterine 
hyperactivity. Even more, it has been shown that the human myometrium is more sensitive 
to AVP than to oxytocin (Bossmar et al., 2007). 
Ang II at concentration of 1 µmol induced tonic contraction with maximum amplitude of 
6.00 ± 0.22 g and an integral force of muscle contraction of 1150.00 ± 614.70 gs. AVP applied 
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in the same concentration as Ang II induced tonic contractions with amplitude of 6.61 ± 0.39 
g (n = 8) and an integral force of muscle contraction of 7245.00 ±901.00 gs. The duration of 
the AVP-induced responses was several times greater than those of Ang II and the recording 
of AVP-mediated contractions was stopped on the 30th minute without achievement of Tchr 
parameter.  
Our experiment confirmed the contractile effect of these two peptides on the myometrium, 
which is in accordance with the results of other authors working on the same issues (Anouar 
et al., 1996; Chan et al., 1996; Keskil et al., 1999). 
The contractions induced by both peptides have similar amplitudes, but they are with 
different duration and characteristics. The registered AVP - provoked uterine responses 
were found to have a sustained oscillating character Figure 6). When analyzed by 
mathematical modeling such contractions were recognized as underdamped process - the 
system tries to establish a stable level different from the baseline (Yankov, 2009). The 
differences in the developed contractions may be due to split of the classical or inclusion of 
additional transduction pathway for each of the studied peptides. Both of them have several 
main groups of receptors. The receptors for Ang II are AT1 and AT2 (De Gasparo et al., 
2000), while the receptors for AVP are V1a, V1b and V2 (Petersen, 2006). 
 
Figure 6. Original record of vasopressin-induced uterine contraction. 
To establish the importance of these receptors for the uterine muscle contraction will be the 
subject of our next experiments. However, several interesting facts immerge: 
First – the constrictor effect of Ang II is associated with AT1 receptors, but the uterus is one of 
the few organs with a. uterina inferior where AT2 receptors are predominant (Keskil et al., 
1999). AT2 receptors are mainly regarded to oppose the effects of AT1 and cause dilation, 
blood pressure reduction, nitric oxide production (Hannan et al., 2003). Perhaps the 
significantly shorter phase of contraction and relaxation was due to their activation under the 
influence of Ang II in the uterus. Second – the constrictor effect of AVP is realized by V1a 
receptors which are found in uterine arteries. With regard to the contractile response of the 
myometrium, however, there are statements that the resulting contraction from the AVP 
influence is due to activation of other receptors, different from the mentioned above (Anouar 
et al., 1996). Some authors go even further and argue that AVP accomplish its effect on uterine 
musculature by OT receptors, which have big similarity with V1 receptors (Chan et al., 1996).  
Considering that both peptides are released from supraoptic nuclei in the hypothalamus 
and that they have a powerful contractile effect on the smooth muscle, it is appropriate to 
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search a closer connection between them in preparing the uterus for pregnancy and labor. 
Probably these two peptides act synchronously which potentiate their own effects (Douglas 
et al.,2001).  
Studies on rats show that AVP is more potent uterotonic agent than OT in non pregnant 
condition (Bossmar et al., 2007) and during parturition OT predominantly promotes uterine 
contractions, while AVP is more important for vasoconstriction, thus reducing the bleeding 
after delivery (Chan et al., 1996; Douglas et al.,2001). 
The study of Ang II – and AVP – mediated uterine contractions contributes considerably for 
the revealing of the mechanisms that generate and modulate uterine activity. This could be 
beneficial for a better understanding and control of myometrial dysfunction. 
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